The MultiPepT1De Study—Examining the Safety of Peptide Immunotherapy Using Multiple Islet Antigens in Recent-Onset Type 1 Diabetes
YF Liu(Loma Linda University Medical Center), Mark Peakman(Sanofi (France)), Moira H. Thomson(Mars (United Kingdom)), Mamta Joshi(Guy's and St Thomas' NHS Foundation Trust), Foteini Strimenopoulou(Mars (United Kingdom)), Emma Smith(UCB Pharma (United Kingdom)), Jake Powrie(Guy's and St Thomas' NHS Foundation Trust), Nikolaos Fountoulakis(Guy's and St Thomas' NHS Foundation Trust), Sefina Arif(Guy's Hospital)
Cited by 3
Related Papers
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
|Diabetes Care|2019|350
Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes
|Diabetes|2014|244
Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes
|Science Translational Medicine|2017|215
Peripheral and Islet Interleukin-17 Pathway Activation Characterizes Human Autoimmune Diabetes and Promotes Cytokine-Mediated β-Cell Death
|Diabetes|2011|213
Hydrophobic CDR3 residues promote the development of self-reactive T cells
|Nature Immunology|2016|185